Pharmacological skills for targeting EGFR and VEGF;Outils pharmacologiques du ciblage du récepteur du facteur de croissance épidermique et du VEGF

Bulletin du Cancer

Volumn 92, Issue SPEC. ISS., 2005, Pages

  Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Colorectal cancer; EGFR; Monoclonal antibody; Targeted therapy; VEGF

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CHEMOSENSITIVITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; PREDICTION; PROTEIN DOMAIN; REVIEW; SKILL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 30044442826     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Lièvre A, Laurent-Puig P. Mécanismes de la cancérogenèse colorectale: acquisitions récentes. Rev Prat 2004; 53: 143-50.
2. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18: S54-9.
3. Boxer GM, Tsiompanou E, Levine T, Watson R, Begent RH. Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer. Tumour Biol 2005; 26: 1-8.
4. Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, et al. Relevance of biologic markers in colorectal carcinoma. Cancer 2002; 94: 647-57.
5. Tabernero J, Salazar R, Casado E, Martinelli E, Gomez P, Baselga J. Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol 2004; 15: 55-62.
6. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 2004; 54: S32-9.
7. Wray CJ, Rilo HL, Ahmad SA. Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 2004; 13: 631-41.
8. Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005; 32: 61-8.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
11. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2002; 94: 1593-611.
12. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer 2004; 91: 418-24.
13. st century? Oncology 18; 18: 736-41.
14. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
15. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108: 464-72.
16. Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (Folfiri) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004; 10: 6522-7.
17. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004; 15: 1007-12.
18. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
19. Fan Z, Masui H, Altas I, Mendelsohn J. Blocade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322-8.
20. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-43.
21. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20 4292-302.
22. Chun KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
23. Paez JG, Janne PA, Lee JC, Tracy S, Grenlich H, Gabriel, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
24. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883.
25. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
26. Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 2004; 31: 3-9.
27. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10.
28. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2003; 36: 748-53.
29. Falm E. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90: 1-7.
30. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-IC11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323-32.
31. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225-33.
32. Morimoto AM, Tan N, West K, McArthur G, Toner GC, Manning WC, et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004; 23: 1618-26.
33. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, et al. Soluble markers for the assessment of biological activity with PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558-65.
34. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288: 371-8.
35. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
36. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotry WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
37. Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005; 32: 61-8.